Post hoc analysis of the PROTECT trial (404 adults with IgA nephropathy): complete proteinuria remission by week 110 (21%) was associated with smaller eGFR decline (-4.0 vs -8.6 ml/min/1.73 m²) and fewer composite kidney end points (1% vs 14%).
Secondary analysisn = 404
Heerspink et al. Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy